Name of Drug: Rolipram (an existing antidepressant)
Manufacturer: Schering AG, Germany, but research for MS by National Institute of Neurological Disorders and Strokes (NINDS) in Bethesda, MD
Current FDA Phase: Phase II: Safety, Tolerability and Effects of Rolipram on Inflammatory Activity in the CNS in MS: Open Label Crossover Trial Using MRI as an Outcome Measure, has been completed.
Treatment: Novel immunomodulatory therapy in MS patients.
Intended for: RRMS, SPMS (i.e., Phase II study included 52 people with EDSS between 1.5 and 6.5)
Mode of Action: ? “..examine whether Rolipram can dampen the part of the immune response believed to lead to MS and reduce disease activity.”
Mode of Application: Oral
Website for more information: http://clinicaltrials.gov/ct/show/NCT00011375?order=18
Other: Some time ago Odd Duck submitted an article on the anti-depressant desipramine as a novel approach to MS treatment so I was fascinated to find the anti-depressant rolipram in a clinical trial for MS. Since this research was done by the NINDS, the results of the Phase II trial, when available, should be public and not proprietary.
For those who have a scientific background (that would NOT be me
), there is an abstract, PMID 7585041, entitled “The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalitis.”
And another abstract, PMID 10430048, entitled, Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones
, that concludes: This profile suggests that rolipram differs from other currently used immunomodulatory drugs.